MORE►
Tricia D’Cruz
L to R: Almaden Genomics CEO David Gascoigne, Executive Chairperson Tricia D'Cruz, and Chief Scientific Officer Mark Kunitomi. [Photos: Almaden Genomics]
Three Months After Launching With Its g.nome Platform, Almaden Genomics Names CEO
by David Seeley | Jan 30, 2023
Life sciences industry veteran David Gascoigne will lead the new startup, which was launched in October by Catalyze Dallas Holdings.
Almaden's g.nome cloud-native platform offers "an advanced visual drag-and-drop workflow builder" and curated library of toolkits that can speed bioinformatic pipeline building "from what previously has taken months to mere hours," the company says.
by Lance Murray |
Jan 17, 2023
Dallas Innovates and D CEO celebrated 68 honorees and revealed the winners of our fourth-annual Innovation Awards at an event held at On the Levee in the Dallas Design District.
Here's a full list of winners and finalists.
MORE►
by Lance Murray |
Nov 3, 2022
Now in its fourth year, the program from Dallas Innovates and D CEO honors 68 disruptors and trailblazers driving a new vision for innovation in North Texas.
Finalists will be recognized in the January/February issue of D CEO magazine and online at DallasInnovates.com. Winners will be revealed at an exclusive awards event in January.
MORE►
by Kevin Cummings |
Oct 25, 2022
The Dallas-based venture development firm—which specializes in the commercialization of technology it acquires from Fortune 100 companies—has launched Almaden Genomics, a company with a newly released platform designed to streamline genomic workflows. Formerly part of IBM Research before its acquisition by Catalyze Dallas, Almaden calls its g.nome platform "a revolutionary approach to bioinformatics."
“The possibilities for the healthcare innovation it can power are as vast as they are life-changing," says Mark Kunitomi, Almaden's chief scientific officer.
MORE►
